Mastocytosis: current concepts in diagnosis and treatment

被引:151
作者
Escribano, L
Akin, C
Castells, M
Orfao, A
Metcalfe, DD
机构
[1] Hosp Ramon & Cajal, Unidad Mastocitosis, E-28034 Madrid, Spain
[2] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA
[3] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[4] Univ Salamanca, Ctr Invest Canc, Serv Cent Citometria, Salamanca 37007, Spain
关键词
mastocytosis; mast cells; mast cell mediators; diagnosis; therapy;
D O I
10.1007/s00277-002-0575-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mastocytosis consists of a group of disorders characterized by a pathologic increase in mast cells in tissues including skin, bone marrow, liver, spleen, and lymph nodes. Mastocytosis is a rare disease. Because of this, general practitioners have limited exposure to its clinical manifestations, diagnosis, classification, and management. Diagnosis of mastocytosis is suspected on clinical grounds and is established by histopathologic examination of involved tissues such as skin and bone marrow. The most common clinical sign of mastocytosis is the presence of typical skin lesions of urticaria pigmentosa. Most patients experience symptoms related to mast cell mediator release, and prevention of the effects of these mediators on tissues constitutes the major therapeutic goal in the management of mastocytosis. Despite recent advances in knowledge about the pathophysiology, diagnosis, and classification of mastocytosis, a curative treatment for mastocytosis does not now exist. Management of patients within all categories of mastocytosis includes: (1) a careful counseling of patients (parents in pediatric cases) and care providers, (2) avoidance of factors triggering acute mediator release, (3) treatment of acute mast cell mediator release, (4) treatment of chronic mast cell mediator release, and if indicated (5) an attempt to treat organ infiltration by mast cells. The goal of this manuscript is to provide an overview of the mediators produced and released by mast cells, the diagnostic criteria for the different variants of mastocytosis, and the treatment options currently available.
引用
收藏
页码:677 / 690
页数:14
相关论文
共 180 条
  • [1] Abraham E K, 1992, Indian J Cancer, V29, P192
  • [2] Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology
    Akin, C
    Schwartz, LB
    Kitoh, T
    Obayashi, H
    Worobec, AS
    Scott, LM
    Metcalfe, DD
    [J]. BLOOD, 2000, 96 (04) : 1267 - 1273
  • [3] An immunohistochemical study of the bone marrow lesions of systemic mastocytosis - Expression of stem cell factor by lesional mast cells
    Akin, C
    Jaffe, ES
    Raffeld, M
    Kirshenbaum, AS
    Daley, T
    Noel, P
    Metcalfe, DD
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2002, 118 (02) : 242 - 247
  • [4] Surrogate markers of disease in mastocytosis
    Akin, C
    Metcalfe, DD
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2002, 127 (02) : 133 - 136
  • [5] AKIN C, 2000, BLOOD, V99, pS3231
  • [6] DISODIUM-CROMOGLYCATE IN THE TREATMENT OF SYSTEMIC MASTOCYTOSIS INVOLVING ONLY BONE
    ALEXANDER, RR
    [J]. ACTA HAEMATOLOGICA, 1985, 74 (02) : 108 - 110
  • [7] Alto WA, 1999, AM FAM PHYSICIAN, V59, P3047
  • [8] Referred for management of mastocytosis
    Apter, AJ
    Rothe, MJ
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1997, 79 (01) : 21 - 26
  • [9] SULFIDOPEPTIDE LEUKOTRIENES IN ASTHMA
    ARM, JP
    LEE, TH
    [J]. CLINICAL SCIENCE, 1993, 84 (05) : 501 - 510
  • [10] SYSTEMIC MASTOCYTOSIS
    AUSTEN, KF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (09) : 639 - 640